Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Acrux, Ltd.
Court overrides stem cell clinic’s dismissal of drug GMPs, the US FDA upbraids drug makers for quality unit shortfalls, and a variety of snafus trigger drug recalls.
Experts convened by FDA to discuss female sexual dysfunction disorders, including problems with desire and arousal, settle on endpoints contrary to new DSM, but are in line with trials of Sprout’s flibanserin, the leading drug in development.
PharmAsia News combs through earnings reports to bring you highlights on Australian biotech firms. We start with CSL Ltd, Acrux, Pharmaxis and Mesoblast for the period ended Dec. 31, 2012.
Public unlisted Australian drug development company Hunter Immunology is recommending that its shareholders accept the takeover offer from listed biotech firm Probiomics.
- Drug Delivery
- Generic Drugs
- Specialty Pharmaceuticals
- Topical Delivery
- Other Names / Subsidiaries
- FemPharm Pty